PE20060287A1 - INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM - Google Patents
INMUNOGLOBULINAS DE UNION SELECTIVA A hOSMInfo
- Publication number
- PE20060287A1 PE20060287A1 PE2005000360A PE2005000360A PE20060287A1 PE 20060287 A1 PE20060287 A1 PE 20060287A1 PE 2005000360 A PE2005000360 A PE 2005000360A PE 2005000360 A PE2005000360 A PE 2005000360A PE 20060287 A1 PE20060287 A1 PE 20060287A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdrh1
- hosm
- osm30
- cdrl1
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 230000003993 interaction Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
REFERIDA A UN ANTICUERPO 15E10 O 10D3, QUE PUEDE SER QUIMERICO, HUMANO, HUMANIZADO, BIESPECIFICO O FRAGMENTOS DE UNION A ANTIGENO DEL MISMO, QUE COMPRENDE RESIDUOS CDR SELECCIONADOS DE CDRH3 DE SECUENCIA N° ID 3, CDRH1 DE SEC N° ID 1, CDRH2 DE SEC N° ID 2, CDRL1 DE SEC N° ID 4, CDRL2 DE SEC N° ID 5, CDRL3 DE SEC N° ID 6, CDRH3 DE SEC N° ID 42, CDRH1 DE SEC N° ID 40, CDRH2 DE SEC N° ID 41, CDRL1 DE SEC N° ID 43, CDRL2 DE SEC N° ID 44 Y CDRL3 DE SEC N° ID 45. ADICIONALMENTE PUEDE COMPRENDER UNA CADENA PESADA SELECCIONADA DE IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4 Y IgM Y UNA CADENA LIGERA. TAMBIEN SE REFIERE A PROCEDIMIENTOS DE PRODUCCION Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHO ANTICUERPO, EL CUAL SE UNE ESPECIFICAMENTE A ONCOSTATINA M (OSM) Y EN PARTICULAR AL SITIO II DE OSM HUMANA (hOSM) Y MODULA LA INTERACCION ENTRE OSM Y gp130, POR LO QUE ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES ARTRITICAS TALES COMO ARTRITIS REUMATOIDE Y/O OSTEOARTRITIS, ENTRE OTRAS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0407193A GB0407193D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
| GB0407197A GB0407197D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060287A1 true PE20060287A1 (es) | 2006-05-16 |
Family
ID=35064447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000360A PE20060287A1 (es) | 2004-03-30 | 2005-03-29 | INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7858753B2 (es) |
| EP (2) | EP2404935A1 (es) |
| JP (1) | JP4809828B2 (es) |
| KR (1) | KR100942849B1 (es) |
| AR (1) | AR048516A1 (es) |
| AT (1) | ATE515515T1 (es) |
| AU (1) | AU2005229457B2 (es) |
| BR (1) | BRPI0509367A (es) |
| CA (1) | CA2562953A1 (es) |
| CY (1) | CY1112192T1 (es) |
| DK (1) | DK1730191T3 (es) |
| HR (1) | HRP20110657T1 (es) |
| IL (1) | IL178119A0 (es) |
| MA (1) | MA28541B1 (es) |
| NO (1) | NO20064886L (es) |
| NZ (1) | NZ550225A (es) |
| PE (1) | PE20060287A1 (es) |
| PL (1) | PL1730191T3 (es) |
| PT (1) | PT1730191E (es) |
| RU (5) | RU2429245C2 (es) |
| SG (1) | SG151292A1 (es) |
| SI (1) | SI1730191T1 (es) |
| TW (1) | TWI365746B (es) |
| WO (1) | WO2005095457A2 (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法 |
| WO2007098547A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| BRPI0711908B8 (pt) * | 2006-05-25 | 2021-05-25 | Glaxo Group Ltd | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| PL2305300T3 (pl) | 2008-07-10 | 2016-09-30 | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
| WO2010016526A1 (ja) | 2008-08-05 | 2010-02-11 | 東レ株式会社 | 癌の治療及び予防用医薬組成物 |
| CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
| US8309688B2 (en) * | 2008-12-30 | 2012-11-13 | Centocor Ortho Biotech Inc. | Monkey homolog of human oncostatin M and methods of use thereof |
| EP2258723A1 (en) * | 2009-06-02 | 2010-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of oncostatin M receptor ß mediated heart failure |
| MX340016B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| US8937160B2 (en) | 2010-02-04 | 2015-01-20 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| ES2540858T3 (es) | 2010-02-04 | 2015-07-14 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención de cáncer |
| PL2532365T3 (pl) | 2010-02-04 | 2016-12-30 | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| KR101758117B1 (ko) | 2010-02-04 | 2017-07-14 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
| CA2814652C (en) * | 2010-10-13 | 2021-05-18 | Janssen Biotech, Inc. | Human oncostatin m antibodies and methods of use |
| UY33743A (es) * | 2010-11-23 | 2012-06-29 | Glaxo Group Ltd | Proteínas de unión a antígenos |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| TR201808595T4 (tr) | 2011-08-04 | 2018-07-23 | Toray Industries | Kanser hastalıklarının tedavisi ve/veya profilaksisi için farmasötik bileşim. |
| PT2740795T (pt) | 2011-08-04 | 2017-01-09 | Toray Industries | Composição de fármaco para o tratamento e/ou a prevenção de cancro |
| PL2818481T3 (pl) | 2012-02-21 | 2020-02-28 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi złośliwemu |
| AU2013223147B2 (en) | 2012-02-21 | 2017-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| EP2818483B1 (en) | 2012-02-21 | 2017-08-02 | Toray Industries, Inc. | Medicinal composition for treating and/or preventing cancer |
| HUE044611T2 (hu) | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| PT2832366T (pt) | 2012-03-30 | 2018-01-25 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar |
| JP6107654B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
| KR101882366B1 (ko) | 2013-05-30 | 2018-07-30 | 키닉사 파마슈티컬스, 리미티드 | 온코스타틴 m 수용체 항원 결합 단백질 |
| EP3031826B1 (en) | 2013-08-09 | 2018-10-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| US9550828B2 (en) | 2013-09-05 | 2017-01-24 | Boise State University | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders |
| DK3089994T3 (da) | 2013-12-30 | 2022-07-04 | Epimab Biotherapeutics Inc | Fabs-in-tandem-immunglobulin og anvendelser deraf |
| SI3110434T1 (sl) * | 2014-02-24 | 2019-02-28 | Takeda Gmbh | UTI fuzijski proteini |
| US20170327573A1 (en) * | 2014-09-24 | 2017-11-16 | Universitá Degli Studi Di Padova | Composition to induce bone marrow stem cell mobilization |
| CN107209177A (zh) * | 2015-01-29 | 2017-09-26 | 阿雷斯贸易股份有限公司 | 用于高正电荷蛋白的免疫测定法 |
| CU24613B1 (es) | 2016-02-06 | 2022-07-08 | Epimab Biotherapeutics Inc | Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr |
| CN108883176A (zh) | 2016-03-28 | 2018-11-23 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| AU2019263850A1 (en) | 2018-05-03 | 2020-11-19 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
| FR3090637A1 (fr) * | 2018-12-21 | 2020-06-26 | Universite De Poitiers | Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations. |
| US11633457B2 (en) | 2019-04-11 | 2023-04-25 | Boise State University | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use |
| MX2023004500A (es) | 2020-10-19 | 2023-05-10 | Zoetis Services Llc | Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos. |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| SK285046B6 (sk) | 1991-07-25 | 2006-05-04 | Idec Pharmaceuticals Corporation | Chimérna protilátka, ktorá sa špecificky viaže na ľudský antigén, farmaceutický prostriedok s jej obsahom, spôsob jej výroby a použitie |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| JP3622208B2 (ja) | 1993-06-11 | 2005-02-23 | 東ソー株式会社 | 骨粗鬆症治療方法及び治療薬 |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| DE69920897T2 (de) | 1998-04-28 | 2005-10-13 | Smithkline Beecham Corp. | Monoklonale antikörper mit verringerter immunisierungsfähigkeit |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
-
2005
- 2005-03-29 PE PE2005000360A patent/PE20060287A1/es not_active Application Discontinuation
- 2005-03-29 NZ NZ550225A patent/NZ550225A/en not_active IP Right Cessation
- 2005-03-29 HR HR20110657T patent/HRP20110657T1/hr unknown
- 2005-03-29 RU RU2006134477/10A patent/RU2429245C2/ru not_active IP Right Cessation
- 2005-03-29 US US10/594,293 patent/US7858753B2/en not_active Expired - Fee Related
- 2005-03-29 PT PT05733043T patent/PT1730191E/pt unknown
- 2005-03-29 AT AT05733043T patent/ATE515515T1/de active
- 2005-03-29 EP EP11167424A patent/EP2404935A1/en not_active Withdrawn
- 2005-03-29 SG SG200901959-7A patent/SG151292A1/en unknown
- 2005-03-29 CA CA002562953A patent/CA2562953A1/en not_active Abandoned
- 2005-03-29 AU AU2005229457A patent/AU2005229457B2/en not_active Ceased
- 2005-03-29 PL PL05733043T patent/PL1730191T3/pl unknown
- 2005-03-29 WO PCT/GB2005/001147 patent/WO2005095457A2/en not_active Ceased
- 2005-03-29 EP EP05733043A patent/EP1730191B1/en not_active Expired - Lifetime
- 2005-03-29 BR BRPI0509367-8A patent/BRPI0509367A/pt not_active IP Right Cessation
- 2005-03-29 SI SI200531371T patent/SI1730191T1/sl unknown
- 2005-03-29 JP JP2007505621A patent/JP4809828B2/ja not_active Expired - Fee Related
- 2005-03-29 DK DK05733043.3T patent/DK1730191T3/da active
- 2005-03-29 KR KR1020067022671A patent/KR100942849B1/ko not_active Expired - Fee Related
- 2005-03-30 AR ARP050101233A patent/AR048516A1/es unknown
- 2005-03-30 TW TW094110049A patent/TWI365746B/zh not_active IP Right Cessation
-
2006
- 2006-09-14 IL IL178119A patent/IL178119A0/en unknown
- 2006-10-18 MA MA29397A patent/MA28541B1/fr unknown
- 2006-10-26 NO NO20064886A patent/NO20064886L/no not_active Application Discontinuation
-
2009
- 2009-03-10 RU RU2009108149/10A patent/RU2009108149A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108148/10A patent/RU2009108148A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108147/10A patent/RU2009108147A/ru not_active Application Discontinuation
-
2010
- 2010-11-16 US US12/947,371 patent/US20110245470A1/en not_active Abandoned
-
2011
- 2011-05-30 RU RU2011121419/10A patent/RU2011121419A/ru not_active Application Discontinuation
- 2011-09-29 CY CY20111100943T patent/CY1112192T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060287A1 (es) | INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM | |
| PE20121689A1 (es) | Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos | |
| PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| PE20191102A1 (es) | Anticuerpos anti-pd-1 y sus usos | |
| PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
| PE20091342A1 (es) | Inmunoglobulinas | |
| PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| PE20060418A1 (es) | Anticuerpos antagonistas de il-17 | |
| PE20131400A1 (es) | Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9) | |
| PE20121397A1 (es) | Anticuerpos especificos para cadherina-17 | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20060376A1 (es) | ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3 | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| PE20120211A1 (es) | Anticuerpos que tienen especificidad por ox40 humana | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| HRP20180252T1 (hr) | Molekule humaniziranih antitijela specifični za il-31 | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20081186A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| PE20140633A1 (es) | Anticuerpos neutralizadores anti-ccl20 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |